OraSure Technologies Inc
OSUR2.710USD
-0.020-0.73%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
195.84MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über OraSure Technologies Inc Unternehmen
OraSure Technologies, Inc. transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The Company improves the access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers. Its products and services include OraQuick ADVANCE Rapid HIV1/2 Antibody Test, OraQuick HIV Self-Test, and Diagnostics Direct Syphilis Health Check.
OraSure Technologies Inc Informationen
BörsenkürzelOSUR
Name des UnternehmensOraSure Technologies Inc
IPO-datumNov 17, 1986
CEOEglinton Manner (Carrie)
Anzahl der mitarbeiter501
WertpapierartOrdinary Share
GeschäftsjahresendeNov 17
Addresse220 E First St
StadtBETHLEHEM
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl18015
Telefon15036416115
Websitehttps://www.orasure.com/
BörsenkürzelOSUR
IPO-datumNov 17, 1986
CEOEglinton Manner (Carrie)
Führungskräfte von OraSure Technologies Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-12524.00%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
163.61K
+10286.00%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+2100.00%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+63040.00%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+66018.00%
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jason Plagman
Mr. Jason Plagman
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Robert W. Mcmahon
Mr. Robert W. Mcmahon
Independent Director
Independent Director
--
--
Ms. Anne Messing
Ms. Anne Messing
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Steven K. (Steve) Boyd
Mr. Steven K. (Steve) Boyd
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
448.46K
-12524.00%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Chairman of the Board
Independent Chairman of the Board
163.61K
+10286.00%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
160.25K
+2100.00%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+63040.00%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+66018.00%
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Net product and services revenues - HIV
14.50M
53.53%
Net product and services revenues - Microbiome
10.31M
38.05%
Other revenues - Other non Product revenues
1.75M
6.46%
Net product and services revenues - Other Products revenue
442.00K
1.63%
Other revenues
442.00K
1.63%
Andere
-353.00K
-1.30%
Nach RegionUSD
Name
Umsatz
Anteil
United States
19.66M
72.59%
Africa (Region)
4.88M
18.00%
Europe
1.30M
4.80%
Other Regions
1.25M
4.61%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Net product and services revenues - HIV
14.50M
53.53%
Net product and services revenues - Microbiome
10.31M
38.05%
Other revenues - Other non Product revenues
1.75M
6.46%
Net product and services revenues - Other Products revenue
442.00K
1.63%
Other revenues
442.00K
1.63%
Andere
-353.00K
-1.30%
Aktionärsstatistik
Aktualisiert: Sat, Nov 15
Aktualisiert: Sat, Nov 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.72%
Altai Capital Management, L.P.
5.21%
Andere
67.85%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
7.81%
Private Management Group, Inc.
7.55%
Neuberger Berman, LLC
5.86%
The Vanguard Group, Inc.
5.72%
Altai Capital Management, L.P.
5.21%
Andere
67.85%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
37.18%
Investment Advisor/Hedge Fund
27.01%
Hedge Fund
23.55%
Individual Investor
6.13%
Research Firm
2.26%
Pension Fund
0.47%
Bank and Trust
0.29%
Venture Capital
0.11%
Family Office
0.01%
Andere
2.99%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
443
65.15M
90.83%
-17.13M
2025Q3
451
66.91M
93.28%
-15.50M
2025Q2
473
72.08M
98.55%
-16.70M
2025Q1
483
70.23M
93.78%
-12.52M
2024Q4
475
70.81M
94.94%
-10.37M
2024Q3
471
70.30M
94.28%
-10.80M
2024Q2
477
73.05M
98.74%
-8.54M
2024Q1
473
74.45M
97.36%
-5.59M
2023Q4
464
73.29M
99.74%
-5.62M
2023Q3
456
72.50M
98.73%
-4.51M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
5.60M
7.81%
+164.29K
+3.02%
Sep 30, 2025
Private Management Group, Inc.
5.42M
7.55%
-44.15K
-0.81%
Sep 30, 2025
Neuberger Berman, LLC
4.20M
5.86%
+46.91K
+1.13%
Sep 30, 2025
The Vanguard Group, Inc.
4.13M
5.76%
-35.41K
-0.85%
Sep 30, 2025
Altai Capital Management, L.P.
3.74M
5.21%
-8.00K
-0.21%
Dec 17, 2025
Dimensional Fund Advisors, L.P.
3.64M
5.07%
-200.81K
-5.23%
Sep 30, 2025
Systematic Financial Management, L.P.
2.52M
3.52%
+293.37K
+13.16%
Sep 30, 2025
Renaissance Technologies LLC
2.26M
3.15%
-15.20K
-0.67%
Sep 30, 2025
Acadian Asset Management LLC
2.12M
2.96%
-67.10K
-3.06%
Sep 30, 2025
Millennium Management LLC
2.11M
2.94%
+878.15K
+71.14%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.44%
iShares US Small Cap Value Factor ETF
0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.05%
iShares Micro-Cap ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Avantis US Small Cap Equity ETF
0.02%
WisdomTree US SmallCap Fund
0.02%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
DFA Dimensional US Small Cap Value ETF
0.01%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.44%
iShares US Small Cap Value Factor ETF
Anteil0.12%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Anteil0.05%
iShares Micro-Cap ETF
Anteil0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.04%
Avantis US Small Cap Equity ETF
Anteil0.02%
WisdomTree US SmallCap Fund
Anteil0.02%
ProShares UltraPro Russell2000
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
DFA Dimensional US Small Cap Value ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
